T2 Biosystems price target raised to 18c from 7c at Alliance Global Partners

Alliance Global Partners analyst Ben Haynor raised the firm’s price target on T2 Biosystems to 18c from 7c and keeps a Neutral rating on the shares. The company reported Q2 revenue inline with the preannounced figure, but its operating loss was greater than anticipated, the analyst tells investors in a research note. The firm says T2’s balance sheet improvement “allows investors to at least glance at the company’s upcoming catalysts.”